Are there meaningful biomarkers of treatment response for depression?

Drug Discovery Today

Volumn 19, Issue 5, 2014, Pages 539-561

  Breitenstein, Barbara ^a,b   Scheuer, Sandra ^b   Holsboer, Florian ^a,b  

^a HolsboerMaschmeyer NeuroChemie   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ANTIDEPRESSANT AGENT; GENETIC MARKER;

DEPRESSION; ELECTROPHYSIOLOGY; FUNCTION TEST; GENE EXPRESSION; GENETIC VARIABILITY; METABOLOMICS; NEUROIMAGING; PROTEOMICS; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; GENETIC MARKER; GENETICS; HUMAN; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSION; GENETIC MARKERS; GENETIC VARIATION; HUMANS; TREATMENT OUTCOME;

EID: 84901352589     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.02.002     Document Type: Review

References (318)

1. R.C. Kessler et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication Arch. Gen. Psychiatry 62 2005 593 602
2. World Health Organization Figures and facts about suicide 1999 World Health Organization Geneva
3. L.V. Kessing, and F.M. Nilsson Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses J. Affect. Disord. 73 2003 261 269
4. H.S. Lett et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment Psychosom. Med. 66 2004 305 315
5. M.J. Knol et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis Diabetologia 49 2006 837 845
6. K.S. Kendler et al. Causal relationship between stressful life events and the onset of major depression Am. J. Psychiatry 156 1999 837 841
7. A.A. Ariyo et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans Circulation 102 2000 1773 1779
8. J. Angst et al. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions J. Affect. Disord. 84 2005 149 157
9. J.M. Pyne et al. Preliminary longitudinal assessment of quality of life in patients with major depression Psychopharmacol. Bull. 33 1997 23 29
10. C. Heim, and C.B. Nemeroff Neurobiology of posttraumatic stress disorder CNS Spectr. 14 2009 13 24
11. P. Zimmermann et al. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study Am. J. Psychiatry 168 2011 1107 1116
12. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin. Pharmacol. Ther. 69 2001 89 95
13. E.R. De Kloet et al. Stress and the brain: from adaptation to disease Nat. Rev. Neurosci. 6 2005 463 475
14. A.J. Rush et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am. J. Psychiatry 163 2006 1905 1917
15. S. Horstmann, and E.B. Binder Pharmacogenomics of antidepressant drugs Pharmacol. Ther. 124 2009 57 73
16. M. Uhr et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression Neuron 57 2008 203 209
17. M. Gex-Fabry et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response Ther. Drug Monit. 30 2008 474 482
18. M. Kato et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 398 404
19. G. Nikisch et al. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study Pharmacol. Res. 58 2008 344 347
20. C. Dong et al. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1 CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans Mol. Psychiatry 14 2009 1105 1118
21. J.E. Sarginson et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression Pharmacogenet. Genomics 20 2010 467 475
22. K-M. Lin et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment Pharmacogenet. Genomics 21 2010 163 170
23. A.B. Singh et al. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression Transl. Psychiatry 2 2012 1 6
24. X. Huang et al. ABCB6 ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients Pharmacogenomics 14 2013 1723 1730
25. B. Breitenstein et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study CNS Spectr. 23 2013 1 11
26. B. Laika et al. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline Clin. Chem. 52 2006 893 895
27. E.J. Peters et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample PLoS ONE 3 2008 e1872
28. A. Mihaljevic Peles et al. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 1439 1444
29. P. Menu et al. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study Neuropsychobiology 62 2010 193 197
30. Y. Dwivedi et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects Arch. Gen. Psychiatry 60 2003 804 815
31. R.H. Perlis et al. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients Biol. Psychiatry 67 2010 1110 1113
32. F.E. O'Brien et al. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings Br. J. Pharmacol. 165 2012 289 312
33. T. Niitsu et al. Pharmacogenetics in major depression: a comprehensive meta-analysis Prog. Neuropsychopharmacol. Biol. Psychiatry 45 2013 183 194
34. S. Porcelli et al. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism Expert Opin. Drug Metab. Toxicol. 7 2011 1101 1115
35. M. Ingelman-Sundberg Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol. Sci. 25 2004 193 200
36. I. D'Empaire et al. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J. Psychiatr. Pract. 17 2011 330 339
37. A.H. Veefkind et al. Venlafaxine serum levels and CYP2D6 genotype Ther. Drug Monit. 22 2000 202 208
38. A.I. Nichols et al. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status J. Clin. Psychopharmacol. 29 2009 383 386
39. T. Rau et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study Clin. Pharmacol. Ther. 75 2004 386 393
40. K.W. Lobello et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder J. Clin. Psychiatry 71 2010 1482 1487
41. M.E.E. Shams et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine J. Clin. Pharm. Ther. 31 2006 493 502
42. K. Grasmäder et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting Eur. J. Clin. Pharmacol. 60 2004 329 336
43. M-H. Tsai et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response Pharmacogenomics 11 2010 537 546
44. A. Serretti et al. Cytochrome P450 CYP1A2, CYP2C9 CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients Int. Clin. Psychopharmacol. 24 2009 250 256
45. D.A. Mrazek et al. CYP2C19 variation and citalopram response Pharmacogenet. Genomics 21 2011 1 9
46. K. Hodgson, and K. Tansey Genetic differences in cytochrome P450 enzymes and antidepressant treatment response J. Psychopharmacol. 28 2014 133 141
47. S. Narasimhan, and F.W. Lohoff Pharmacogenetics of antidepressant drugs: current clinical practice and future directions Pharmacogenomics 13 2012 441 464
48. S. Porcelli et al. Pharmacogenetics of antidepressant response J. Psychiatry Neurosci. 36 2011 87 113
49. O.F. O'Leary et al. Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man Pharmacol. Biochem. Behav. 2013 10.1016/j.pbb.2013.10.015
50. K.P. Lesch et al. The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication J. Neural Transm. 104 1997 1259 1266
51. E. Smeraldi et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine Mol. Psychiatry 3 1998 508 511
52. S. Porcelli et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy Eur. Neuropsychopharmacol. 22 2012 239 258
53. N. Goldman et al. The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms Depress. Anxiety 27 2010 260 269
54. H. Kunugi et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder Mol. Psychiatry 2 1997 457 462
55. D. Mrazek et al. SLC6A4 variation and citalopram response Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 150 2009 341 351
56. J. Staeker et al. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients Genet. Test. Mol. Biomarkers 18 2014 20 31
57. S. Sahraian et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness in Iranian patients with major depressive disorder Iran. J. Psychiatry 8 2013 86 91
58. R.E. Poland et al. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression Life Sci. 92 2013 967 970
59. M. Kato et al. 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial J. Clin. Psychopharmacol. 33 2013 131 132
60. W. Myung et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans Psychopharmacology (Berl.) 225 2013 283 290
61. N. Dreimüller et al. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression Pharmacopsychiatry 45 2012 108 113
62. E-S. Won et al. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder Neuropsychobiology 66 2012 221 229
63. G. Lewis et al. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial Br. J. Psychiatry 198 2011 464 471
64. J.R. Rundell et al. Serotonin transporter gene promotor polymorphism (5-HTTLPR) associations with number of psychotropic medication trials in a tertiary care outpatient psychiatric consultation practice Psychosomatics 52 2011 147 153
65. L.H. Muhonen et al. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence Psychiatry Res. 186 2011 53 57
66. W. Umene-Nakano et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism J. Psychopharmacol. 24 2010 1764 1771
67. S-H. Lee et al. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine Neuropsychobiology 62 2010 198 206
68. F. Reimherr et al. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine Psychiatry Res. 175 2010 67 73
69. A. Baffa et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression Neuropsychobiology 62 2010 121 131
70. R. Yoshimura et al. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients Hum. Psychopharmacol. Clin. Exp. 24 2009 489 494
71. F. Gressier et al. 5-HTTLPR modulates antidepressant efficacy in depressed women Psychiatr. Genet. 19 2009 195 200
72. W. Min et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response Psychopharmacology (Berl.) 205 2009 409 417
73. P. Huezo-Diaz et al. Moderation of antidepressant response by the serotonin transporter gene Br. J. Psychiatry 195 2009 30 38
74. E. Maron et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression Eur. Neuropsychopharmacol. 19 2009 451 456
75. M.J. Wilkie et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy Pharmacogenomics J. 9 2009 61 70
76. K.M. Smits et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients Psychiatr. Genet. 18 2008 184 190
77. O. Dogan et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients Genet. Test. 12 2008 225 231
78. F.E. Lotrich et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients J. Psychiatry Neurosci. 33 2008 123 130
79. N. Bozina et al. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder World J. Biol. Psychiatry 9 2008 190 197
80. S. Kronenberg et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders J. Child Adolesc. Psychopharmacol. 17 2007 741 750
81. R-H. Kang et al. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 1317 1321
82. X-Z. Hu et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression Arch. Gen. Psychiatry 64 2007 783 792
83. J.B. Kraft et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample Biol. Psychiatry 61 2007 734 742
84. J. Kirchheiner et al. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment Pharmacogenomics J. 7 2007 48 55
85. H. Kim et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression JAMA 296 2006 1609 1618
86. E. Smeraldi et al. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants Psychiatr. Genet. 16 2006 153 158
87. C.H. Ng et al. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 953 957
88. M. Kato et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients Neuropsychobiology 53 2006 186 195
89. C-J. Hong et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder Pharmacogenomics J. 6 2006 27 33
90. J.B. Kraft et al. Sequence analysis of the serotonin transporter and associations with antidepressant response Biol. Psychiatry 58 2005 374 381
91. M. Kato et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism Int. Clin. Psychopharmacol. 20 2005 151 156
92. G.M. Murphy et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression Arch. Gen. Psychiatry 61 2004 1163 1169
93. K. Yoshida et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms Am. J. Psychiatry 161 2004 1575 1580
94. E.J. Peters et al. Investigation of serotonin-related genes in antidepressant response Mol. Psychiatry 9 2004 879 889
95. A. Serretti et al. Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up Pharmacogenetics 14 2004 607 613
96. A. Serretti et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 129 2004 36 40
97. L.K. Durham et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder Psychopharmacology (Berl.) 174 2004 525 529
98. M-S. Lee et al. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment Psychiatr. Genet. 14 2004 111 115
99. F.J. McMahon et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment Am. J. Hum. Genet. 78 2006 804 814
100. S. Horstmann et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment Neuropsychopharmacology 35 2010 727 740
101. S. Lucae et al. HTR2A gene variation is involved in antidepressant treatment response Eur. Neuropsychopharmacol. 20 2010 65 68
102. R. Uher et al. Genetic predictors of response to antidepressants in the GENDEP project Pharmacogenomics J. 9 2009 225 233
103. A. Serretti et al. No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression Psychiatry Investig. 10 2013 180 189
104. A.K. Tiwari et al. Analysis of 34 candidate genes in bupropion and placebo remission Int. J. Neuropsychopharmacol. 16 2013 771 781
105. Z. Xu et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response J. Psychopharmacol. 26 2012 349 359
106. T. Kishi et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort Neuromol. Med. 12 2010 237 242
107. E.J. Peters et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response Pharmacogenet. Genomics 19 2009 1 10
108. A. Illi et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression Neuroreport 20 2009 1125 1128
109. R.H. Perlis et al. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder Biol. Psychiatry 65 2009 785 791
110. S. Horstmann et al. Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients Eur. Neuropsychopharmacol. 18 2008 S214 S215
111. R-H. Kang et al. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression Int. J. Psychiatry Med. 37 2007 315 329
112. M-J. Choi et al. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram Neuropsychobiology 52 2005 155 162
113. A. Serretti et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity Eur. Neuropsychopharmacol. 11 2001 375 380
114. A. Serretti et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity Mol. Psychiatry 6 2001 586 592
115. B-J. Ham et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 104 107
116. B-J. Ham et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population Psychiatr. Genet. 15 2005 299 301
117. M. Kato et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression Neuropsychobiology 56 2007 167 171
118. H-C. Wang et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients Psychopharmacology (Berl.) 213 2011 773 779
119. S-J. Tsai et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response Prog. Neuropsychopharmacol. Biol. Psychiatry 33 2009 637 641
120. M.V. Tzvetkov et al. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment Pharmacogenet. Genomics 18 2008 495 506
121. M. Viikki et al. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response Neurosci. Lett. 468 2010 80 84
122. S.Z. Sabol et al. A functional polymorphism in the monoamine oxidase A gene promoter Hum. Genet. 103 1998 273 279
123. D. Tzeng et al. MAOA Gene polymorphisms and response to mirtazapine in major depression Hum. Psychopharmacol. 24 2009 293 300
124. K. Domschke et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 224 228
125. Y.W-Y. Yu et al. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response Neuropsychopharmacology 30 2005 1719 1723
126. A.F. Leuchter et al. Monoamine oxidase A and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder J. Clin. Psychopharmacol. 29 2009 372 377
127. A. Tadić et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 144 2007 325 331
128. A. Szegedi et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression Pharmacogenomics J. 5 2005 49 53
129. B. Arias et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin J. Affect. Disord. 90 2006 251 256
130. K. Yoshida et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran Hum. Psychopharmacol. Clin. Exp. 23 2008 121 128
131. B.T. Baune et al. Association of the COMT val158met variant with antidepressant treatment response in major depression Neuropsychopharmacology 33 2008 924 932
132. S-J. Tsai et al. Sexually dimorphic effect of catechol-O- methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients J. Affect. Disord. 113 2009 183 187
133. F. Benedetti et al. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting Psychopharmacology (Berl.) 203 2009 155 160
134. F. Benedetti et al. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine Eur. Psychiatry 25 2010 476 478
135. D. Spronk et al. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study J. Affect. Disord. 128 2011 41 48
136. N.A. Kocabas et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study Int. Clin. Psychopharmacol. 25 2010 218 227
137. J.P. Houston et al. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder Psychiatry Res. 189 2011 475 477
138. S. Paddock et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort Am. J. Psychiatry 164 2007 1181 1188
139. A. Serretti et al. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression Neuropsychobiology 65 2012 70 75
140. M. Pu et al. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response Pharmacogenomics 14 2013 277 288
141. G. Xu et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population Psychiatr. Genet. 22 2012 214 215
142. W.D. Taylor et al. The BDNF Val66Met genotype and six-month remission rates in late-life depression Pharmacogenomics 11 2011 146 154
143. M.H. Chi et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder J. Affect. Disord. 126 2010 430 435
144. Y-F. Zou et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients Neuropsychobiology 61 2010 71 78
145. K. Yoshida et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine J. Psychopharmacol. 21 2007 650 656
146. M-J. Choi et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder Brain Res. 1118 2006 176 182
147. A. Katsuki et al. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD) CNS Spectr. 17 2012 155 163
148. R. Yoshimura et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1022 1025
149. R.H. Kang et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression J. Psychopharmacol. 24 2010 1755 1763
150. E. Lin et al. Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders Pharmgenomics Pers. Med. 1 2008 1 6
151. M.J. Wilkie et al. A splice site polymorphism in the G-protein β subunit influences antidepressant efficacy in depression Pharmacogenet. Genomics 17 2007 207 215
152. J. Licinio et al. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response Arch. Gen. Psychiatry 66 2009 488 497
153. M. Gratacòs et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders Pharmacogenomics J. 8 2008 101 112
154. N.A. Kocabas et al. Brain-derived neurotrophic factor gene polymorphisms Int. Clin. Psychopharmacol. 26 2011 1 10
155. K. Domschke et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response Int. J. Neuropsychopharmacol. 13 2010 93 101
156. A. Illi et al. No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin Psychiatr. Genet. 23 2013 33 35
157. G.M. Murphy et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression Pharmacogenet. Genomics 23 2013 301 313
158. J.M. Hennings et al. Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach PLoS ONE 8 2013 e64947
159. F. Holsboer The corticosteroid receptor hypothesis of depression Neuropsychopharmacology 23 2000 477 501
160. E.B. Binder The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders Psychoneuroendocrinology 34 2009 S186 S195
161. T. Jääskeläinen et al. Steroid up-regulation of FKBP51 and its role in hormone signaling Curr. Opin. Pharmacol. 11 2011 326 331
162. P.D. Reynolds et al. Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51 J. Clin. Endocrinol. Metab. 84 1999 663 669
163. E.B. Binder et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment Nat. Genet. 36 2004 1319 1325
164. J. Kirchheiner et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment Pharmacogenomics 9 2008 841 846
165. S-J. Tsai et al. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 144 2007 1097 1098
166. S. Papiol et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment J. Affect. Disord. 104 2007 83 90
167. M. Lekman et al. The FKBP5-gene in depression and treatment response - an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort Biol. Psychiatry 63 2008 1103 1110
168. J.E. Sarginson et al. FKBP5 polymorphisms and antidepressant response in geriatric depression Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 153 2010 554 560
169. A. Zobel et al. DNA sequence variants of the FKBP5 gene are associated with unipolar depression Int. J. Neuropsychopharmacol. 13 2010 649 660
170. M. Ising et al. The combined dexamethasone/CRH test as a potential surrogate marker in depression Prog. Neuropsychopharmacol. Biol. Psychiatry 29 2005 1085 1093
171. Y-F. Zou et al. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders Neurosci. Lett. 484 2010 56 61
172. K.A. Ellsworth et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder Pharmacogenet. Genomics 23 2013 156 166
173. P.M. Lizardi et al. Genome-wide approaches for cancer gene discovery Trends Biotechnol. 29 2011 558 568
174. A. Sequeira et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression PLoS ONE 4 2009 e6585
175. E. Sibille et al. A molecular signature of depression in the amygdala Am. J. Psychiatry 166 2009 1011 1024
176. J.Z. Li et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions Hum. Mol. Genet. 13 2004 609 616
177. D. Mehta et al. Gene expression studies in major depression Curr. Psychiatry Rep. 12 2010 135 144
178. A.E. Baird The blood option: transcriptional profiling in clinical trials Pharmacogenomics 7 2006 141 144
179. M.E. Burczynski, and A.J. Dorner Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies Pharmacogenomics 7 2006 187 202
180. B. Rollins et al. Analysis of whole genome biomarker expression in blood and brain Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 153 2010 919 936
181. P.F. Sullivan et al. Evaluating the comparability of gene expression in blood and brain Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 141 2006 261 268
182. R. Yehuda et al. Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks Biol. Psychiatry 66 2009 708 711
183. D. Mehta et al. Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies Arch. Gen. Psychiatry 68 2011 901 910
184. R.H. Segman et al. Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors Mol. Psychiatry 10 2005 500 513
185. H. Le-Niculescu et al. Identifying blood biomarkers for mood disorders using convergent functional genomics Mol. Psychiatry 14 2009 156 174
186. R.C. Padmos et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes Arch. Gen. Psychiatry 65 2008 395 407
187. S.M. Kurian et al. Identification of blood biomarkers for psychosis using convergent functional genomics Mol. Psychiatry 16 2011 37 58
188. R.H. Segman et al. Blood mononuclear cell gene expression signature of postpartum depression Mol. Psychiatry 15 2010 93 100
189. S. Spijker et al. Stimulated gene expression profiles as a blood marker of major depressive disorder Biol. Psychiatry 68 2010 179 186
190. A. Menke et al. Dexamethasone stimulated gene expression in peripheral
191. A. Morag et al. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker Pharmacogenomics 12 2011 171 184
192. M. Ising et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol. Psychiatry 62 2007 47 54
193. C.M. Pariante Glucocorticoid receptor function in vitro in patients with major depression Stress 7 2004 209 219
194. C.M. Pariante, and A.H. Miller Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment Biol. Psychiatry 49 2001 391 404
195. E.F.C. Van Rossum et al. Polymorphisms of the glucocorticoid receptor gene and major depression Biol. Psychiatry 59 2006 681 688
196. M. Nibuya et al. Repeated stress increases catalytic TrkB mRNA in rat hippocampus Neurosci. Lett. 267 1999 81 84
197. M.J. Schaaf et al. Corticosterone effects on BDNF expression in the hippocampus. Implications for memory formation Stress 3 2000 201 208
198. A. Russo-Neustadt et al. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression Neuropsychopharmacology 21 1999 679 682
199. H.D. Schmidt, and R.S. Duman The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior Behav. Pharmacol. 18 2007 391 418
200. C.H. Duman et al. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise Behav. Brain Res. 198 2009 366 371
201. J.L. Warner-Schmidt, and R.S. Duman VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants Proc. Natl. Acad. Sci. U. S. A. 104 2007 4647 4652
202. A.H. Miller, and H.K. Manji On redefining the role of the immune system in psychiatric disease Biol. Psychiatry 60 2006 796 798
203. N. Müller et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Mol. Psychiatry 11 2006 680 684
204. A.C. Linthorst et al. Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature Endocrinology 135 1994 520 532
205. H. Himmerich et al. Regulatory T cells increased while IL-1β decreased during antidepressant therapy J. Psychiatr. Res. 44 2010 1052 1057
206. J. Hannestad et al. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis Neuropsychopharmacology 36 2011 2452 2459
207. J. Brunner et al. Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters Eur. Arch. Psychiatry Clin. Neurosci. 255 2005 438 440
208. C. Ditzen et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology Neuropsychopharmacology 37 2012 1013 1025
209. C. Piubelli et al. Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: Environmental challenge Int. J. Neuropsychopharmacol. 14 2011 834 855
210. M.D. Filiou et al. Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways Biol. Psychiatry 70 2011 1074 1082
211. D. Martins-de-Souza et al. The role of proteomics in depression research Eur. Arch. Psychiatry Clin. Neurosci. 260 2010 499 506
212. A.R. Fernie et al. Metabolite profiling: from diagnostics to systems biology Nat. Rev. Mol. Cell Biol. 5 2004 763 769
213. D.S. Wishart Metabolomics in humans and other mammals S.G. Villas-Boas, Metabolome Analysis: An Introduction 2007 John Wiley & Sons 255 256
214. R. Kaddurah-Daouk et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept Transl. Psychiatry 1 2011 1 7
215. T.A. Clayton et al. Pharmaco-metabonomic phenotyping and personalized drug treatment Nature 440 2006 1073 1077
216. E.J. Sachar et al. Corticosteroid responses to psychotherapy of depressions Arch. Gen. Psychiatry 16 1967 461 470
217. C.B. Nemeroff et al. Elevated concentrations of CSF corticotropin- releasing factor-like immunoreactivity in depressed patients Science 226 1984 1342 1344
218. F.C. Raadsheer et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients Neuroendocrinology 60 1994 436 444
219. C.B. Nemeroff et al. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims Arch. Gen. Psychiatry 45 1988 577 579
220. B.J. Carroll et al. A specific laboratory test for the diagnosis of Melancholia Depressi Arch. Gen. Psychiatry 38 1981 15 22
221. G.W. Arana et al. The dexamethasone suppression test for diagnosis and prognosis in psychiatry Arch. Gen. Psychiatry 42 1985 1193 1204
222. W.A. Brown et al. Dexamethasone suppression test identifies subtypes of depression which respond to different antidepressants Lancet 1 1980 928 929
223. W.A. Brown, and C.B. Qualls Pituitary-adrenal disinhibition in depression: marker of a subtype with characteristic clinical features and response to treatment? Psychiatry Res. 4 1981 115 128
224. M.A. Schlesser et al. Hypothalamic-pituitary-adrenal axis activity in depressive illness Arch. Gen. Psychiatry 37 1980 737
225. Y. Papakostas et al. Neuroendocrine measures in psychiatric patients: course and outcome with ECT Psychiatry Res. 4 1981 55 64
226. F. Holsboer et al. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement J. Affect. Disord. 4 1982 93 101
227. S.C. Ribeiro et al. The DST as a predictor of outcome in depression: a meta-analysis Am. J. Psychiatry 150 1993 1618 1629
228. P.W. Gold et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor Am. J. Psychiatry 141 1984 619 627
229. F. Holsboer et al. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression N. Engl. J. Med. 311 1984 1127
230. P.W. Gold, and G.P. Chrousos Clinical studies with corticotropin releasing factor: implications for the diagnosis and pathophysiology of depression, Chushing's disease and adrenal insufficiency Psychoneuroendocrinology 10 1985 401 419
231. F. Holsboer, and N. Barden Antidepressants and hypothalamic-pituitary- adrenocortical regulation Endocr. Rev. 17 1996 187 205
232. F. Holsboer et al. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression Biol. Psychiatry 22 1987 228 234
233. U. Von Bardeleben et al. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls Int. Clin. Psychopharmacol. 4 Suppl. 1 1989 1 5
234. I. Heuser et al. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders J. Psychiatr. Res. 28 1994 341 356
235. M. Deuschle et al. The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression test Biol. Psychiatry 43 1998 762 766
236. S. Watson et al. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression Psychol. Med. 32 2002 1021 1028
237. H. Kunugi et al. Combined DEX/CRH test among Japanese patients with major depression J. Psychiatr. Res. 38 2004 123 128
238. A.W. Zobel et al. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression Am. J. Psychiatry 156 1999 949 951
239. A.W. Zobel et al. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study J. Psychiatr. Res. 35 2001 83 94
240. H. Kunugi et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study Neuropsychopharmacology 31 2006 212 220
241. E. Holsboer-Trachsler et al. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment - neurobiological and psychometric assessment of course J. Psychiatr. Res. 28 1994 381 399
242. C. Schüle et al. Attenuation of hypothalamic-pituitary- adrenocortical hyperactivity in depressed patients by mirtazapine Psychopharmacology (Berl.) 166 2003 271 275
243. T. Nickel et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression J. Clin. Psychopharmacol. 23 2003 155 168
244. C. Schüle et al. The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression PLoS ONE 4 2009 e4324
245. U. Hegerl, and G. Juckel Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis Biol. Psychiatry 33 1993 173 187
246. J. Gallinat et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression Psychopharmacology (Berl.) 148 2000 404 411
247. T-W. Lee et al. Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression J. Psychiatry Neurosci. 30 2005 202 205
248. G. Juckel et al. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder J. Clin. Psychiatry 68 2007 1206 1212
249. T. Linka et al. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression Pharmacopsychiatry 38 2005 139 143
250. T.W. Picton The P300 wave of the human event-related potential J. Clin. Neurophysiol. 9 1992 456 479
251. B. Kalayam, and G.S. Alexopoulos Prefrontal dysfunction and treatment response in geriatric depression Arch. Gen. Psychiatry 56 1999 713 718
252. G. Ulrich et al. Interrelation between changes in the EEG and psychopathology under pharmacotherapy for endogenous depression. A contribution to the predictor question Pharmacopsychiatry 17 1984 178 183
253. G.E. Bruder et al. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings Biol. Psychiatry 63 2008 1171 1177
254. G.E. Bruder et al. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant Biol. Psychiatry 49 2001 416 425
255. A.F. Leuchter et al. Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography Neuroimage 1 1994 208 219
256. A.F. Leuchter et al. Relationship between brain electrical activity and cortical perfusion in normal subjects Psychiatry Res. 90 1999 125 140
257. M. Bares et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder Eur. Psychiatry 23 2008 350 355
258. M. Bares et al. The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments Eur. Neuropsychopharmacol. 20 2010 459 466
259. I.A. Cook et al. Early changes in prefrontal activity characterize clinical responders to antidepressants Neuropsychopharmacology 27 2002 120 131
260. I.A. Cook et al. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study J. Psychiatr. Res. 39 2005 461 466
261. I.A. Cook et al. Midline and right frontal brain function as a physiologic biomarker of remission in major depression Psychiatry Res. 174 2009 152 157
262. M. Kopecek et al. Can prefrontal theta cordance differentiate between depression recovery and dissimulation? Neuro Endocrinol. Lett. 28 2007 524 526
263. M. Kopecek et al. QEEG changes during switch from depression to hypomania/mania: a case report Neuro Endocrinol. Lett. 29 2008 295 302
264. J.M. Broadway et al. Frontal theta cordance predicts 6-month antidepressant response to subcallosal cingulate deep brain stimulation for treatment-resistant depression: a pilot study Neuropsychopharmacology 37 2012 1764 1772
265. M. Pawlowski et al. Cordance as a biomarker in sleep-EEG for depression: responders versus nonresponders: a naturalistic study after antidepressant medication Eur. Neuropsychopharmacol. 21 Suppl. 3 2011 360 361
266. A.M. Hunter et al. Does prior antidepressant treatment of major depression impact brain function during current treatment? Eur. Neuropsychopharmacol. 22 2012 711 720
267. A.F. Leuchter et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study Psychiatry Res. 169 2009 124 131
268. A.F. Leuchter et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder Psychiatry Res. 169 2009 132 138
269. R.D. Pascual-Marqui et al. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain Int. J. Psychophysiol. 18 1994 49 65
270. A.F. Leuchter et al. Biomarkers to predict antidepressant response Curr. Psychiatry Rep. 12 2010 553 562
271. D.A. Pizzagalli Electroencephalography and high-density electrophysiological source localization J.T. Cacioppo, Handbook of Pathophysiology 3rd edn 2007 56 84
272. R.D. Pascual-Marqui et al. Functional imaging with low-resolution brain electromagnetic tomography (LORETA): a review Methods Find. Exp. Clin. Pharmacol. 24 Suppl. C 2002 91 95
273. R.D. Pascual-Marqui Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details Methods Find. Exp. Clin. Pharmacol. 24 Suppl. D 2002 5 12
274. D. Pizzagalli et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis Am. J. Psychiatry 158 2001 405 415
275. A.M. Hunter et al. Rostral anterior cingulate activity in major depressive disorder: state or trait marker of responsiveness to medication? J. Neuropsychiatry Clin. Neurosci. 25 2013 126 133
276. A. Steiger, and M. Kimura Wake and sleep EEG provide biomarkers in depression J. Psychiatr. Res. 44 2010 242 252
277. M.E. Thase et al. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy Arch. Gen. Psychiatry 53 1996 99 108
278. M.A. Dew et al. Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly Arch. Gen. Psychiatry 54 1997 1016 1024
279. A.J. Rush et al. Reduced REM latency predicts response to tricyclic medication in depressed outpatients Biol. Psychiatry 26 1989 61 72
280. K. Svendsen, and P.G. Christensen Duration of REM sleep latency as predictor of effect of antidepressant therapy. A preliminary report Acta Psychiatr. Scand. 64 1981 238 243
281. J.H. Heiligenstein et al. Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients Psychiatry Res. 52 1994 327 339
282. D.J. Kupfer et al. EEG sleep changes as predictors in depression Am. J. Psychiatry 133 1976 622 626
283. D.J. Kupfer et al. Sleep and treatment prediction in endogenous depression Am. J. Psychiatry 138 1981 429 434
284. D.J. Kupfer, and M.E. Thase The use of the sleep laboratory in the diagnosis of affective disorders Psychiatr. Clin. North Am. 6 1983 3 25
285. J.C. Gillin et al. The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline Psychopharmacology (Berl.) 59 1978 267 272
286. D. Höchli et al. Initial REM sleep suppression by clomipramine: a prognostic tool for treatment response in patients with a major depressive disorder Biol. Psychiatry 21 1986 1217 1220
287. H. Murck et al. State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine Neuropsychopharmacology 28 2003 348 358
288. M. Kimura et al. Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep Mol. Psychiatry 15 2010 154 165
289. F. Holsboer, and M. Ising Stress hormone regulation: biological role and translation into therapy Annu. Rev. Psychol. 61 2010 81 109
290. D.A. Pizzagalli Frontocingulate dysfunction in depression: toward biomarkers of treatment response Neuropsychopharmacology 36 2011 183 206
291. C. Mulert et al. Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication Clin. EEG Neurosci. 38 2007 78 81
292. A.S. Korb et al. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression Clin. Neurophysiol. 120 2009 1313 1319
293. C-H. Chen et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment Biol. Psychiatry 62 2007 407 414
294. R.J. Davidson et al. The neural substrates of affective processing in depressed patients treated with venlafaxine Am. J. Psychiatry 160 2003 64 75
295. S.A. Langenecker et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder Biol. Psychiatry 62 2007 1272 1280
296. G. Salvadore et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine Biol. Psychiatry 65 2009 289 295
297. H.S. Mayberg et al. Cingulate function in depression: a potential predictor of treatment response Neuroreport 8 1997 1057 1061
298. M.S. Milak et al. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment Psychiatry Res. 173 2009 63 70
299. J. Wu et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex Am. J. Psychiatry 156 1999 1149 1158
300. A. Anand et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study Biol. Psychiatry 57 2005 1079 1088
301. K.J. Ressler, and H.S. Mayberg Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic Nat. Neurosci. 10 2007 1116 1124
302. S.F. Taylor, and I. Liberzon Neural correlates of emotion regulation in psychopathology Trends Cogn. Sci. 11 2007 413 418
303. A. Anand et al. Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study Neuropsychopharmacology 30 2005 1334 1344
304. F.A. Kozel et al. Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder Front. Psychiatry 2 2011 7
305. S. Campbell et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis Am. J. Psychiatry 161 2004 598 607
306. M.C. McKinnon et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder J. Psychiatry Neurosci. 34 2009 41 54
307. P. Videbech, and B. Ravnkilde Hippocampal volume and depression: a meta-analysis of MRI studies Am. J. Psychiatry 161 2004 1957 1966
308. M. Ballmaier et al. Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex Am. J. Psychiatry 161 2004 99 108
309. J.D. Bremner et al. Reduced volume of orbitofrontal cortex in major depression Biol. Psychiatry 51 2002 273 279
310. T. Hajek et al. Reduced subgenual cingulate volumes in mood disorders: a meta-analysis J. Psychiatry Neurosci. 33 2008 91 99
311. T. Frodl et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study J. Psychiatry Neurosci. 33 2008 423 430
312. G.M. MacQueen et al. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder Biol. Psychiatry 64 2008 880 883
313. K. Vakili et al. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study Biol. Psychiatry 47 2000 1087 1090
314. K. Yucel et al. Increased subgenual prefrontal cortex size in remitted patients with major depressive disorder Psychiatry Res. 173 2009 71 76
315. G.S. Alexopoulos et al. Frontal white matter microstructure and treatment response of late-life depression: a preliminary study Am. J. Psychiatry 159 2002 1929 1932
316. G.S. Alexopoulos et al. Microstructural white matter abnormalities and remission of geriatric depression Am. J. Psychiatry 165 2008 238 244
317. P.G. Sämann et al. Prediction of antidepressant treatment response from gray matter volume across diagnostic categories Eur. Neuropsychopharmacol. 23 2013 1503 1515
318. S. Leucht et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses Br. J. Psychiatry 200 2012 97 106